© Bluebee

A GLOBAL CLOUD BASEDBIO-INFORMATICS PLATFORM FOR GENOMICS

My background

1987 1999 2002 2006 2010 2014

Bluebee Scaling-Up : from Technology to Customer Focus

Founded Market validation with select academic customers

Software platform live

Library of reference solutions developed

ISO27001Full commercial

launch

ISO1348515 active customers

Global rollout begins.FY 2018B ARR signup of $5M

2011 2014 2015 2016 2017 Now

3 9 20 31 34

Delft (NL) Mechelen (BE) Rijswijk (NL) Boston (US) San Francisco (US)

Bluebee Scaling-Up : Funding

2011 2014 2015 2016 2017 Now

250K Loan 1.8M Convertible 10M Series A 4M Series A extension

Series B

Biover II

...

Our Team : The Right Mix of Business and Science

Edmée van Dijk, CFOJoined 2015Previously investment manager at Delft University of Technology, overseeing Bluebee since 2012

Hans Cobben, CEOJoined 2013Serial entrepreneur. Previously built several scalable global data processing companies, which he successfully sold to technology giants

Kurt Florus, CTOJoined 201515+ years of experience in building large scale mission-critical data platforms

Marc Hogenbirk, Chief Science OfficerJoined 2015Ph.D. in cancer genetics

Vlad-Mihai Sima, Head of ResearchCo-founderPh.D. in computer engineering

Vicky Buyse, CCOJoined 201717+ years of experience in life science and diagnostics industries

Marc Gielis, COOJoined 2016Held senior operating roles in various ICT companies

Lars KongsbakAdvisor and investor

Nicolas RoelofsAdvisor and investor

Michelle Garred, Head of MarketingJoined 201816+ years of genomics experience

What exactly is “Genomics” ?

NGS and Precision Medicine : One Drives the Other

Next-Generation Sequencing (NGS) costs have plummeted

And the use of sequencing has soared

Enabling the growth of precision medicine

› Precision medicine considers individual variability in genes in the treatment and prevention of diseases

› Key applications: • Oncology• Infectious diseases• Inherited diseases • Reproductive health

› The precision medicine market is projected to grow from $44B in 2016 to over $140B by 2026

Cost per raw megabase of DNA sequence Global install base of NGS instruments

Sources: National Human Genome Research Institute, JP Morgan, BIS Research, Research and Markets

0

2

4

6

8

10

12

14

16

18

Uni

ts in

thou

sand

s

2009 2011 2013 201720150.01

0.10

1.00

10

100

1,000

10,000

(in $

)

2001 2006 2012 2017

“Data handling is now the bottleneck. It costs more to analyze a genome than to sequence a genome.”

The Resulting Data Explosion Triggers the Need for Better Genome Data Analysis and Interpretation

“The field of bioinformatics for genetic analysis will be one of the biggest areas of disruptive innovation in life science tools over the next few years.”

David Haussler PhD, Distinguished Professor

Isaac RoLife Sciences research analyst

Bluebee Offering

Our Cloud Service Helps Precision Medicine Companies Make Sense of All This DataThe Bluebee automated software platform:

à Without any need for manual processing by a bioinformatician or other genomics data expert.

Capture data from NGS instruments

Analyze it with reference applications

Interpret the results

Produce aclinical report4321

Belgium : Development & EU Sales teamNetherlands : Bio-informatics & Corporate adminSan Mateo (CA) : Marketing & US Sales

14

Examples

Multidrug-resistant tuberculosis testTests resistance to 13 antibiotics

Breast cancer prognostic testPredicts chance of cancer relapse

Our platform help these two companies gain:

Speed Time to market and rollout speed

Reach Global availability

Quality Uniform quality of analysis

Control Full control of the data

Insight Comprehensive view on test results, patient info, customer usage

Product Expansion: Artificial Intelligence

We are developing an environment that uses artificial intelligence to mine genomic data and identify new links and patterns

Successful proof-of-concept testing completed.Our clients are ecstatic about the new possibilities this opens up.Pilot testing of this AI-enabled environment begins in H1 2019.

Imagine aggregating data of all cancer patients on our platform….

… and the treatment they received…

… and how their cancer progressed…

… and then using artificial intelligence to look at this data and cluster it in different ways in order to identify which treatment patterns produce best outcomes.

Challenge ? Healthcare has relatively slow customer lifecycles.

Technology

TeamScalability

Go-to-market model

Prospect

Signed contract

Onboarding & QC

Validation & certification

Product launch

Volume growth

6-8 months 2-3 months 2-3 months 6+ months

Revenue Generation

© Bluebee

Thank You

Hans Cobben – CEO - hans.cobben@bluebee.com